Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryOct042018	Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations SAN DIEGO , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Wen Bo Wang , Ph.D., a leading expert in the manufacture of Read All »	View HTML
Toggle SummaryApr182019	Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development SAN DIEGO , April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu , M.D. Read All »	View HTML
Toggle SummaryMay102010	Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of Tom Novak, Ph.D., as vice president of research and drug discovery. Dr. Novak brings to Fate more than 15 years of experience working with large pharmaceutical companies, including Roche and Wyeth, to Read All »	View HTML Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery 10.2 KB
Toggle SummaryFeb202019	Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation SAN DIEGO , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Sarah Cooley , M.D., M.S., a leading expert in Read All »	View HTML
Toggle SummaryJun152021	Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer SAN DIEGO , June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic , DVM, PhD, RAC has been appointed Chief Technical Read All »	View HTML
Toggle SummarySep142017	Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company has appointed Jim Beitel, M.B.A. Read All »	View HTML Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 17 KB
Toggle SummaryAug192020	Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer SAN DIEGO , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointed Chief Financial Read All »	View HTML
Toggle SummaryJul152015	Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced today that it has named Dr. Read All »	View HTML Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research 15.1 KB
Toggle SummaryMar172014	Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors. Dr. Read All »	View HTML Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors 84.4 KB
Toggle SummaryOct152012	Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer San Diego, CA – Fate Therapeutics, Inc. announced today that Christian Weyer, M.D., M.A.S. has been appointed President and Chief Executive Officer and elected to the Company’s Board of Directors, Read All »	View HTML Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer 11.3 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.